TrialThe Journal of infectious diseases2026

Switching to Daily Doravirine/Islatravir (100/0.25 mg) Maintains Viral Suppression Through Week 48 Despite Baseline Non-Nucleoside Reverse Transcriptase Inhibitor Resistance-Associated Mutations or M184I/V in Proviral DNA.

Tracy L Diamond et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.